TY - JOUR
T1 - Risks of Proton Pump Inhibitors in Patients with Cirrhosis
T2 - Please Peruse the Indications
AU - Low, En Xian Sarah
AU - Wang, Yen Po
AU - Lu, Ching Liang
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2024/1
Y1 - 2024/1
N2 - The use of proton pump inhibitor (PPI) in cirrhotic patients can be associated with increased risks of long-term mortality, decompensation, hepatic encephalopathy, spontaneous bacterial peritonitis, and infection, but not with short-term mortality. Ensure clear indications at lowest effective dose of is mandatory for the use of PPI among cirrhotic patients.
AB - The use of proton pump inhibitor (PPI) in cirrhotic patients can be associated with increased risks of long-term mortality, decompensation, hepatic encephalopathy, spontaneous bacterial peritonitis, and infection, but not with short-term mortality. Ensure clear indications at lowest effective dose of is mandatory for the use of PPI among cirrhotic patients.
KW - Cirrhosis
KW - Hepatic decompensation
KW - Hepatocellular carcinoma
KW - Proton pump inhibitors
KW - Spontaneous bacterial peritonitis
UR - http://www.scopus.com/inward/record.url?scp=85176783768&partnerID=8YFLogxK
U2 - 10.1007/s10620-023-08153-3
DO - 10.1007/s10620-023-08153-3
M3 - Comment/debate
C2 - 37968555
AN - SCOPUS:85176783768
SN - 0163-2116
VL - 69
SP - 7
EP - 9
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 1
ER -